File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A new paradigm for managing dyslipidemia with combination therapy: Laropiprant + niacin + simvastatin

TitleA new paradigm for managing dyslipidemia with combination therapy: Laropiprant + niacin + simvastatin
Authors
Issue Date2010
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eid
Citation
Expert Opinion On Investigational Drugs, 2010, v. 19 n. 3, p. 437-449 How to Cite?
AbstractImportance of the field: Despite effective lowering of low-density lipoprotein cholesterol (LDL-C) with statin for prevention of cardiovascular adverse events, residual risk remains high due to low high-density lipoprotein cholesterol (HDL-C) levels in patients with mixed dyslipidemia. As a result, alternative treatment options to raise HDL-C are being investigated intensively. Currently, niacin is the most potent lipid lowering agent for raising HDL-C levels together with lowering of triglyceride and LDL-C. Previous clinical studies have demonstrated that niacin therapy significantly reduces the risk of cardiovascular events in high risk subjects. However, the clinical use of niacin is limited by its major adverse effect, cutaneous flushing. Although the use of extended-release (ER) formulation can reduce flushing, the tolerability and compliance of niacin remains suboptimal. A selective antagonist of prostaglandin D Type 1 receptor, laropiprant, has been investigated in a number of clinical studies and shown to be effective in reducing niacin-induced flushing. Despite the potential of laropiprant in reducing niacin-induced flushing, the long-term clinical efficacy and potential off-target side effects are not well studied. Areas covered in this reviews: In this article, the pharmacological properties, clinical efficacy and future perspective of this combination therapy of simvastatin/ER niacin/laropiprant are reviewed. What the reader will gain: Readers will understand both the mechanism and clinical effects of the combination therapy of simvastatin/ER niacin/laropiprant. Take home message: The triple combination therapy of simvastatin/ER niacin/laropiprant may reduce flushing side effects and facilitate a more comprehensive treatment for patients with mixed dyslipidemia. © 2010 Informa UK Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/91521
ISSN
2015 Impact Factor: 4.408
2015 SCImago Journal Rankings: 1.314
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYiu, KHen_HK
dc.contributor.authorCheung, BMYen_HK
dc.contributor.authorTse, HFen_HK
dc.date.accessioned2010-09-17T10:20:44Z-
dc.date.available2010-09-17T10:20:44Z-
dc.date.issued2010en_HK
dc.identifier.citationExpert Opinion On Investigational Drugs, 2010, v. 19 n. 3, p. 437-449en_HK
dc.identifier.issn1354-3784en_HK
dc.identifier.urihttp://hdl.handle.net/10722/91521-
dc.description.abstractImportance of the field: Despite effective lowering of low-density lipoprotein cholesterol (LDL-C) with statin for prevention of cardiovascular adverse events, residual risk remains high due to low high-density lipoprotein cholesterol (HDL-C) levels in patients with mixed dyslipidemia. As a result, alternative treatment options to raise HDL-C are being investigated intensively. Currently, niacin is the most potent lipid lowering agent for raising HDL-C levels together with lowering of triglyceride and LDL-C. Previous clinical studies have demonstrated that niacin therapy significantly reduces the risk of cardiovascular events in high risk subjects. However, the clinical use of niacin is limited by its major adverse effect, cutaneous flushing. Although the use of extended-release (ER) formulation can reduce flushing, the tolerability and compliance of niacin remains suboptimal. A selective antagonist of prostaglandin D Type 1 receptor, laropiprant, has been investigated in a number of clinical studies and shown to be effective in reducing niacin-induced flushing. Despite the potential of laropiprant in reducing niacin-induced flushing, the long-term clinical efficacy and potential off-target side effects are not well studied. Areas covered in this reviews: In this article, the pharmacological properties, clinical efficacy and future perspective of this combination therapy of simvastatin/ER niacin/laropiprant are reviewed. What the reader will gain: Readers will understand both the mechanism and clinical effects of the combination therapy of simvastatin/ER niacin/laropiprant. Take home message: The triple combination therapy of simvastatin/ER niacin/laropiprant may reduce flushing side effects and facilitate a more comprehensive treatment for patients with mixed dyslipidemia. © 2010 Informa UK Ltd.en_HK
dc.languageengen_HK
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eiden_HK
dc.relation.ispartofExpert Opinion on Investigational Drugsen_HK
dc.subject.meshDelayed-Action Preparationsen_HK
dc.subject.meshDrug Therapy, Combinationen_HK
dc.subject.meshDyslipidemias - drug therapy - physiopathologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshHydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects - pharmacology - therapeutic useen_HK
dc.subject.meshHypolipidemic Agents - adverse effects - pharmacology - therapeutic useen_HK
dc.subject.meshIndoles - adverse effects - pharmacology - therapeutic useen_HK
dc.subject.meshNiacin - adverse effects - pharmacology - therapeutic useen_HK
dc.subject.meshSimvastatin - adverse effects - pharmacology - therapeutic useen_HK
dc.titleA new paradigm for managing dyslipidemia with combination therapy: Laropiprant + niacin + simvastatinen_HK
dc.typeArticleen_HK
dc.identifier.emailYiu, KH:khkyiu@hku.hken_HK
dc.identifier.emailCheung, BMY:mycheung@hku.hken_HK
dc.identifier.emailTse, HF:hftse@hkucc.hku.hken_HK
dc.identifier.authorityYiu, KH=rp01490en_HK
dc.identifier.authorityCheung, BMY=rp01321en_HK
dc.identifier.authorityTse, HF=rp00428en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1517/13543781003623223en_HK
dc.identifier.pmid20141348-
dc.identifier.scopuseid_2-s2.0-76949084798en_HK
dc.identifier.hkuros158541-
dc.identifier.hkuros173627-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-76949084798&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume19en_HK
dc.identifier.issue3en_HK
dc.identifier.spage437en_HK
dc.identifier.epage449en_HK
dc.identifier.isiWOS:000274886900010-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridYiu, KH=35172267800en_HK
dc.identifier.scopusauthoridCheung, BMY=7103294806en_HK
dc.identifier.scopusauthoridTse, HF=7006070805en_HK
dc.identifier.citeulike6829278-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats